Theravance Biopharma (TBPH) Stock Forecast & Price Target

$8.28

+0.04 (+0.49%)

(As of 11/1/2024 ET)

Theravance Biopharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 5 Analyst Ratings

Sell
0

Hold
3

Buy
2

Based on 5 Wall Street analysts who have issued ratings for Theravance Biopharma in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 3 have given a hold rating, and 2 have given a buy rating for TBPH.

Consensus Price Target

$13.75
66.06% Upside

According to the 5 analysts' twelve-month price targets for Theravance Biopharma, the average price target is $13.75. The highest price target for TBPH is $21.00, while the lowest price target for TBPH is $9.00. The average price target represents a forecasted upside of 66.06% from the current price of $8.28.

Get the Latest News and Ratings for TBPH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Theravance Biopharma and its competitors.

TBPH Analyst Ratings Over Time

Type	Current Forecast 11/3/23 to 11/2/24	1 Month Ago 10/4/23 to 10/3/24	3 Months Ago 8/5/23 to 8/4/24	1 Year Ago 11/3/22 to 11/3/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$13.75	$13.75	$20.50	$17.00
Forecasted Upside	66.06% Upside	69.75% Upside	112.66% Upside	72.59% Upside
Consensus Rating	Hold	Hold	Buy	Buy

625,000% Gain (Ad)

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

TBPH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TBPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Theravance Biopharma Stock vs. The Competition

Type	Theravance Biopharma	Medical Companies	S&P 500
Consensus Rating Score	2.40	2.79	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	66.06% Upside	15,872.29% Upside	10.56% Upside
News Sentiment Rating	Very Positive News See Recent TBPH News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00	+84.28%
8/6/2024	Leerink Partnrs 5 of 5 stars	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/6/2024	TD Cowen 4 of 5 stars		Lower Target	Hold ➝ Hold	$10.00 ➝ $9.00	+14.50%
8/6/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$15.00 ➝ $10.00	+4.28%
4/12/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$21.00	+135.16%
1/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Inline

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:27 AM ET.

TBPH Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Theravance Biopharma is $13.75, with a high forecast of $21.00 and a low forecast of $9.00.
: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TBPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBPH, but not buy additional shares or sell existing shares.
: According to analysts, Theravance Biopharma's stock has a predicted upside of 66.06% based on their 12-month stock forecasts.
: Over the previous 90 days, Theravance Biopharma's stock had 2 downgrades by analysts.
: Theravance Biopharma has been rated by research analysts at HC Wainwright, Leerink Partners, Leerink Partnrs, and TD Cowen in the past 90 days.
: Analysts like Theravance Biopharma less than other "medical" companies. The consensus rating for Theravance Biopharma is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TBPH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

625,000% Gain (Ad)

>> Dive into the Workshop Here

This page (NASDAQ:TBPH) was last updated on 11/2/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Theravance Biopharma (TBPH) Stock Forecast & Price Target